ClinicalTrials.gg
CompletedNCT03811197TASTYUpdated May 27, 2020

Efficacy of Diet and Hypnotic Suggestions or Telemedicine in Obesity Management

An interventional study of Dietary counseling via face to face meeting and Telemedicine in Obesity and Weight Loss, sponsored by Warsaw University of Life Sciences. Completed at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-27.

Sponsored by Warsaw University of Life Sciences · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Oct 2017, registered Jan 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is the assessment of the effectiveness of medical nutrition therapy (MNT) among obese patients, including a well-balanced low-calories diet, an individual dietary counseling conducted by dietitians and supported by telemedicine (T) or hypnotic suggestions (HS).

The study will cover a group of 90 adult patients, both sexes, with obesity (BMI ≥30 kg/m\^2) undergoing MNT a dietetic treatment. Three arms are planned in the study scheme, according to the scheme: Group 1 - individual MNT (30 people); Group 2 -individual MNT and T (30 people); Group 3 - individual MNT and HS (30 people).

The authors hope that the results of the study will allow to develop a new model of the most effective management of obesity, resulting in weight reduction and maintaining this effect over time. The results obtained during the study will also allow to assess the impact of the therapy applied on lifestyle changes, dietary habits and the knowledge about the disease among obese patients.

Read the detailed description

This is a prospective randomized control trial among obese subjects. The scope of the study includes: identification of nutritional habits leading to obesity; assessment of patient's motivation to introduce life style changes; assessment of anthropometric parameters, body composition, arterial stiffness and resting metabolic rate at baseline and at specific control points; development of individual medical nutrition therapy (MNT) and weight reduction plan depending on the initial body weight of the subjects; quantitative and qualitative assessment of the diet at baseline and in each month for a period of 6 months (Part A) and 9, 12 months (Part B); assessment of nutritional knowledge at baseline and at specific control points; education of patients using the behavioral-cognitive method, conducted for 6 months; introduction of hypnotic suggestion (HS) or telemedicine (T) to support the achievement and the maintenance of the lifestyle changes.

The study covers a group of 90 adults, both sexes, with obesity (BMI ≥30 kg/m\^2), undergoing individual MNT, randomly assigned to one of three groups for 6 months (Part A): Group 1 - individual MNT (30 people); Group 2 - individual MNT and T (30 people); Group 3 - individual MNT and HS (30 people). All subjects will continue the program for additional 6 months (Part B follow up).

The selection of subjects for the study is purposeful and the participation in the study is voluntary. All subjects are educated to follow a reduced calorie Dietary Approaches to Stop Hypertension diet ("DASH") for 6 months (Part A). Education materials (handouts and sample meal plans) are provided to the subjects.

The primary and secondary outcomes will be evaluated at baseline, months 1,2,3,4,5, 6 (Part A) and months 9, 12 (Part B follow up).

02

Conditions studied

  • Obesity
  • Weight Loss

Keywords

  • Obesity
  • Weight Loss
  • Telemedicine
  • Hypnotic Suggestions
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's enrollment of 90 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Warsaw University of Life Sciences is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is over 18 years.
  • Subject is diagnosed with obesity ( ≥ 30 kg / m\^2 at the screening visit).
  • Subject understands the study procedures and is able to give written .

Exclusion criteria

Exclusion Criteria:

  • Subject is under 18 years.
  • Subject is a pregnant women or a breast-feeding mother; or subject is planning to be pregnant during the study period
  • Subject is suffering from chronic liver diseases or renal failure
  • Subject has untreated or uncompensated thyroid diseases
  • Subject has a history of presence of mental disorders
  • Subject has a history of presence of epilepsy
  • Subject has a history of presence of cancer
  • Any other uncontrolled physical or psychological condition that increases significantly the health risks for the subject
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    individual MNT

    Dietary counseling via face to face meeting

    Behavioral: Dietary counseling via face to face meeting

  • Experimental
    Individual MNT and T

    Dietary counseling via face to face meeting and Telemedicine

    Behavioral: Dietary counseling via face to face meeting · Behavioral: Telemedicine

  • Experimental
    Individual MNT and HS

    Dietary counseling via face to face meeting and Hypnotic Suggestions

    Behavioral: Dietary counseling via face to face meeting · Behavioral: Hypnotic Suggestions

Interventions

  • BehavioralDietary counseling via face to face meeting

    All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).

  • BehavioralTelemedicine

    All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).

  • BehavioralHypnotic Suggestions

    All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the "small steps" method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B).

06

What researchers measure

Primary outcomes

  1. Body Weight

    Changes in body weight from baseline (month 0) to each post-randomization visit (month 1, 3, 6 for Parts A and 9, 12 months for Part B)

    Time frame: 6 months (Part A); up to 12 months (Part B)

  2. Body Mass Index

    Changes in BMI from baseline (month 0) to each post-randomization visit (month 1, 3, 6 for Parts A and 9, 12 months for Part B)

    Time frame: 6 months (Part A); up to 12 months (Part B)

Secondary outcomes

  1. Waist circumference

    Changes in waist circumference from baseline (month 0) to each post-randomization visit (month 1, 3, 6 for Parts A and 9, 12 months for Part B)

    Time frame: 6 months (Part A); up to 12 months (Part B)

  2. Hip circumference

    Changes in hip circumference from baseline (month 0) to each post-randomization visit (month 1, 3, 6 for Parts A and 9, 12 months for Part B)

    Time frame: up to 6 months (Part A); up to 12 months (Part B)

  3. Arm circumference

    Changes in arm circumference from baseline (month 0) to each post-randomization visit (month 1, 3, 6 for Parts A and 9, 12 months for Part B)

    Time frame: 6 months (Part A); up to 12 months (Part B)

  4. Body composition

    Changes in body fat mass, fat free mass, muscle mass using bioelectrical impedance analysis from baseline (month 0) to each post-randomization visit (month 1, 3, 6 for Parts A and 9, 18 months for Part B)

    Time frame: 6 months (Part A); up to 12 months (Part B)

  5. Health related quality of life

    Changes in Health related quality of life using the EQ-5D-5L questionnaire

    Time frame: baseline, month 6, 9, 12

  6. Dietary intake

    Changes in dietary intakes using 4-day recorded diet diaries from baseline (month 0) to each post-randomization visit

    Time frame: 6 months (Part A); up to 12 months (Part B)

  7. Sleep behaviour

    Sleep behaviour using Athens Insomnia Scale (AIS)

    Time frame: baseline and month 6 for Parts A and month 12 for Part B

  8. Subjective assessment of health status

    Changes in subjective assessment of health status using 5-points Likert-type rating scale

    Time frame: baseline and month 6 for Parts A and month 12 for Part B

Other outcomes

  1. Arterial stiffness

    Arterial stiffness measurement using an applanation tonometer (Sphygmocor, AtCor Medical, Sydney, Australia

    Time frame: baseline, month 12

  2. Resting Metabolic Rate

    Resting Metabolic Rate measurement using FitMate metabolic system (Cosmed, Rome, Italy)

    Time frame: baseline, month 12

  3. Nutritional knowledge score baseline

    Nutritional knowledge measurement using Nutritional Knowledge 13-items Test

    Time frame: baseline, month 6

  4. The patient's readiness for making changes

    The patient's readiness for making changes assessed by a questionnaire (Intrinsic Motivation Inventory, IMI-SR Motivation Questionnaire) and the scale of perception of own competences

    Time frame: baseline

07

Study locations

1 site
  • Faculty of Human Nutrition and Consumer Sciences of the Warsaw University of Life Sciences
    Warsaw, 02-776, Poland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2019, 20 months.

Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 20 months is below that.

Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2019
First posted
Jan 22, 2019
StartActual
Oct 13, 2017
Primary completionActual
Jun 30, 2019
CompletionActual
Dec 10, 2019
Last update
May 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03811197
Lead sponsor
Warsaw University of Life Sciences
Responsible party
Danuta Gajewska (Principal Investigator, Adjunct Professor at the Department of Dietetics,PhD, Warsaw University of Life Sciences) — Principal investigator
First posted
Jan 22, 2019
Start date
Oct 13, 2017
Primary completion
Jun 30, 2019
Completion
Dec 10, 2019
Last update
May 27, 2020

Study contacts

Danuta Gajewska, PhD
principal investigator · Department of Dietetics, Warsaw University of Life Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion